David X Zhuo1, Katie Ginder2, E Ashley Hardin3. 1. Fellow, Advanced Heart Failure and Transplant Cardiology, Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390-9047, USA. 2. Nurse Practitioner, Advanced Heart Failure, Transplant, LVAD, Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3. Internal Medicine, Advanced Heart Failure and Transplant Cardiology, Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, 5959 Harry Hines Boulevard, Ste #HP.8.110, Dallas, TX, 75390-9047, USA. elizabeth.hardin@utsouthwestern.edu.
Abstract
PURPOSE OF REVIEW: Recent developments in high-throughput DNA and RNA sequencing technologies have facilitated the development of noninvasive assays to monitor heart transplant rejection. In this review, we summarize existing assays employed for the surveillance of allograft rejection, as well as promising future directions for such tests in the molecular biology field. RECENT FINDINGS: The AlloMap genome expression profiling assay remains the only noninvasive test for rejection surveillance and is incorporated into the International Society of Heart and Lung Transplantation guidelines. Other efforts have focused on messenger RNA (mRNA), microRNA (miRNA), and donor-derived cell-free DNA (dd-cfDNA) as potential viable biomarkers. Mitochondrial pathways in allograft necroptosis and inflammation signaling may represent a novel direction for future research endeavors. Although endomyocardial biopsy remains the gold standard, several converging areas of molecular biology could soon yield successful alternative methods of heart transplant rejection monitoring, with the distinct advantage of avoiding procedural complications.
PURPOSE OF REVIEW: Recent developments in high-throughput DNA and RNA sequencing technologies have facilitated the development of noninvasive assays to monitor heart transplant rejection. In this review, we summarize existing assays employed for the surveillance of allograft rejection, as well as promising future directions for such tests in the molecular biology field. RECENT FINDINGS: The AlloMap genome expression profiling assay remains the only noninvasive test for rejection surveillance and is incorporated into the International Society of Heart and Lung Transplantation guidelines. Other efforts have focused on messenger RNA (mRNA), microRNA (miRNA), and donor-derived cell-free DNA (dd-cfDNA) as potential viable biomarkers. Mitochondrial pathways in allograft necroptosis and inflammation signaling may represent a novel direction for future research endeavors. Although endomyocardial biopsy remains the gold standard, several converging areas of molecular biology could soon yield successful alternative methods of heart transplant rejection monitoring, with the distinct advantage of avoiding procedural complications.
Authors: Maria Rosa Costanzo; Anne Dipchand; Randall Starling; Allen Anderson; Michael Chan; Shashank Desai; Savitri Fedson; Patrick Fisher; Gonzalo Gonzales-Stawinski; Luigi Martinelli; David McGiffin; Jon Smith; David Taylor; Bruno Meiser; Steven Webber; David Baran; Michael Carboni; Thomas Dengler; David Feldman; Maria Frigerio; Abdallah Kfoury; Daniel Kim; Jon Kobashigawa; Michael Shullo; Josef Stehlik; Jeffrey Teuteberg; Patricia Uber; Andreas Zuckermann; Sharon Hunt; Michael Burch; Geetha Bhat; Charles Canter; Richard Chinnock; Marisa Crespo-Leiro; Reynolds Delgado; Fabienne Dobbels; Kathleen Grady; W Kao; Jaqueline Lamour; Gareth Parry; Jignesh Patel; Daniela Pini; Jeffrey Towbin; Gene Wolfel; Diego Delgado; Howard Eisen; Lee Goldberg; Jeff Hosenpud; Maryl Johnson; Anne Keogh; Clive Lewis; John O'Connell; Joseph Rogers; Heather Ross; Stuart Russell; Johan Vanhaecke Journal: J Heart Lung Transplant Date: 2010-08 Impact factor: 10.247
Authors: Casey P Shannon; Zsuzsanna Hollander; Darlene L Y Dai; Virginia Chen; Sara Assadian; Karen K Lam; Janet E McManus; Marek Zarzycki; YoungWoong Kim; Ji-Young V Kim; Robert Balshaw; Olof Gidlöf; Jenny Öhman; J Gustav Smith; Mustafa Toma; Andrew Ignaszewski; Ross A Davies; Diego Delgado; Haissam Haddad; Debra Isaac; Daniel Kim; Alice Mui; Miroslaw Rajda; Lori West; Michel White; Shelley Zieroth; Scott J Tebbutt; Paul A Keown; W Robert McMaster; Raymond T Ng; Bruce M McManus Journal: Can J Cardiol Date: 2019-11-25 Impact factor: 5.223
Authors: M C Deng; H J Eisen; M R Mehra; M Billingham; C C Marboe; G Berry; J Kobashigawa; F L Johnson; R C Starling; S Murali; D F Pauly; H Baron; J G Wohlgemuth; R N Woodward; T M Klingler; D Walther; P G Lal; S Rosenberg; S Hunt Journal: Am J Transplant Date: 2006-01 Impact factor: 8.086
Authors: Ji-Young V Kim; Brandon Lee; Pavlos Koitsopoulos; Casey P Shannon; Virginia Chen; Zsuzsanna Hollander; Sara Assadian; Karen Lam; Gordon Ritchie; Janet McManus; W Robert McMaster; Raymond T Ng; Bruce M McManus; Scott J Tebbutt Journal: Clin Chem Date: 2020-08-01 Impact factor: 8.327